The link between neoplastic and atopic diseases
Renata Kozłowska 1  
,   Andrzej Bożek 1  
,   Jerzy Jarząb 1  
More details
Hide details
Katedra i Kliniczny Oddział Chorób Wewnętrznych, Dermatologii i Alergologii w Zabrzu, Wydział Lekarski z Oddziałem Lekarsko-Dentystycznym w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach
Andrzej Bożek   

Katedra i Kliniczny Oddział Chorób Wewnętrznych, Dermatologii i Alergologii, Wydział Lekarski z Oddziałem Lekarsko-Dentystycznym w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach, ul. Skłodowskiej 10, 41-800 Zabrze
Ann. Acad. Med. Siles. 2017;71:371–377
Whether there is a protective or stimulating effect of atopy on the risk of neoplastic disease is an interesting question. Studies that have analyzed the matter to date have proposed various explanations for such an effect. In this study, the prevalence of neoplastic diseases in patients with confirmed atopic diseases compared with a control non-atopic group was analyzed.

Material and methods:
A total of 1451 patients with atopic disease and 1389 control subjects over 35 years of age received a physical examination, a skin-prick test and measurement of IgEs specific to common inhalant allergens. A medical history based on an original questionnaire and analysis of family history for the possible occurrence of neoplastic diseases and allergies were performed. Additionally, tumor markers AFP, CEA, SCC, PSA, Ca15.3, Ca19-9, Ca125, HCG, and CYFRA 21-1 were measured in serum.

The results confirmed no significant difference in the prevalence of most analyzed neoplasms between the groups. Chronic lymphocytic leukemia and chronic myelogenous leukemia were significantly less common in the study group. A negative correlation between the concentration of total IgE in serum and the probability of neoplasm diagnosis in the study group was noted. A higher concentration of serum marker CYFRA 21-1, but without clinical manifestation in patients with atopic disease was observed.

The occurrence of neoplastic diseases is slightly lower in patients with atopic diseases than in the control group without allergies. There were no significant differences in the analyzed serum tumor markers between the groups.

Gonzalez-Perez A., Fernandez-Vidaurre C., Rueda A., Rivero E., Garcia Rodriguez L.A. Cancer incidence in a general population of asthma patients. Pharmacoepidemiol. Drug Saf. 2006; 15(2): 131–138.
Arana A., Wentworth C.E., Fernandez-Vidaurre C., Schlienger R.G., Conde E., Arellano F.M. Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K. Br. J. Dermatol 2010; 163(5): 1036–1043.
Musolino C., Allegra A., Minciullo P.L., Gangemi S. Allergy and risk of hematologic malignances: Associations and mechanisms. Leuk. Res. 2014; 38(10): 1137–1144.
Josephs D.H., Spicer C.J., Corrigan C.J., Gould H.J. Karagiannis S.N. Epidemiological associations of allergy, IgE and cancer. Clin. Exp. Allergy 2013; 43(10): 1110–1123.
Tirado-Rodriguez B., Ortega E., Segura-Medina P., Huerta-Yepez S. TGF-β: An important mediator of allergic disease and a molecule with dual activity in cancer development. J. Immunol. Res 2014; 318481.
Heinzerling L.M., Burbach G.J., Edenharter G., Bachert C., Bindslev-Jensen C., Bonini S. et al. GA(2)LEN skin test study I: GA(2)LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in Europe. Allergy 2009; 64: 1498–1506.
World Health Organization. ICD-10: The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. WHO. Geneva, Switzerland 1992.
Global Initiative for Asthma. GINA Report, Global Strategy for Asthma Management and Prevention. 2014 [dostęp 23.08.2015].
Hanifin J.M., Rajka G. Diagnostic features of atopic dermatitis. Acta Derm. Venerol. Suppl. 1980; 92: 44–47.
Bousquet J., Khaltaev N., Cruz A.A., Denburg J., Fokkens W.J. Togias A. et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63: 8–160.
Bozek A., Kozlowska R., Jarząb, J. The safety of specific immunotherapy for patients allergic to house – dust mites and pollen in relation to the development of neoplasia and autoimmune disease: a long-term, observational case-control study. Int. Arch. Allergy Immunol. 2014; 163(4): 307–312.
Boffeta P., Ye W., Boman G., Nyren D. Lung cancer risk in a population-based cohort of patients hospitalized for asthma in Sweden. Eur. Respir. J. 2002; 19(1): 127–133.
Hwang C.Y., Chen Y.J., Lin M.W., Chen T.J., Chu S.Y., Chen C.C. et al. Cancer risk in patients with allergic rhinitis, asthma and atopic dermatitis: A nationwide cohort study in Taiwan. Int. J. Cancer 2012; 130(5): 1160–1167.
Rosenberger A., Bickeboller H., McCormack V., Brenner D.R., Duell E.J., Tjønneland A. et al. Asthma and lung cancer risk: a systematic investigation by the International Lung Cancer Consortium. Carcinogenesis 2012; 33(3): 587–597.
Olesen A.B., Gerda E., Storm H.H., Thestrup-Pedersen K. The risk of cancer among patients previously hospitalized for atopic dermatitis. J. Investig. Dermatol 2005; 125(3): 445–449.
Denholm R., Schüz J., Straif K., Stücker I., Jöckel K.H., Brenner D.R., et al. Is previous respiratory disease a risk factor for lung cancer? Am. J. Respir. Crit. Care Med 2014; 190(5): 549–559.
Jensen A.O., Thomsen H.F., Engebjerg M.C., Olesen A.B., Friis S., Karagas M.R., Sorensen H.T. Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-base case-control study. Br. J. Cancer 2009; 100(1): 200–205.
Tolak K., Omernik A., Zdan O., Ragus D., Domagała-Kulawik J., Rudzinski P., Chazan R. The frequency of allergy in lung cancer patients. Pneumonol. Alergol. Pol 2006; 74(2): 144–148.
Yarbro J.W., Page D.L., Fielding L.P., Partridge E.E., Murphy G.P. American Joint Committee on Cancer prognostic factors consensus conference. Cancer 1999; 86(11): 2436–2446.
Huang Y.L., Chen J., Yan W., Zang, D., Qin Q., Deng A.M. Diagnostic accuracy of cytokeratin-19 fragment (CYFRA 21-1) for bladder cancer: A systematic review and meta-analysis. Tumour Biol 2015; 36(5): 3137–3145.